The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Open accessAbstract
Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic options for patients who failed to respond to conventional treatment or relapse. Moreover, it can bridge other therapeutic strategies and greatly improve patient prognosis, with broad applicable prospects. Even so, 30-60% patients relapse after treatment, probably due to persistence of CAR T-cells and escape or downregulation of CD19 antigen, which is a great challenge for disease control. Therefore, understanding the mechanisms that underlie post-CAR relapse and establishing corresponding prevention and treatment strategies is important. Herein, we discuss post-CAR relapse from the aspects of CD19-positive and CD19-negative and provide some reasonable prevention and treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 1×
“CD19-Positive Relapse CD19-positive relapse is usually associated with limited persistence, low potency of CARs, low response to CARs in patients, and transient B-cell aplasia (7).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“(48) reported that targeting a CD19-specific CAR coding sequence to the T-cell receptor (TCR) locus, placing it under the control of endogenous regulatory elements, not only led to uniform CAR expression in human peripheral blood Tcells but also promoted T-cell potency.”
BackgroundLong, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Gardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF
Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., Cachero, T. G., Hession, C., Schneider, P., Sizing, I. D., Mullen, C., et al. (2001) · Science · doi:10.1126/science.1061965 · Cited by 889
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 749
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1054-1 · Cited by 654
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Guedan, S., Posey, A. D., Shaw, C., Wing, A., Da, T., Patel, P. R., McGettigan, S. E., Casado-Medrano, V., Kawalekar, O. U., Uribe-Herranz, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96976 · Cited by 580
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., Levine, J. E., Qayed, M., Grupp, S. A., Boyer, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0146-z · Cited by 575
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87366 · Cited by 558
What is trogocytosis and what is its purpose?
Joly, E., & Hudrisier, D. (2003) · Nature Immunology · doi:10.1038/ni0903-815 · Cited by 543
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Martinelli, G., Boissel, N., Chevallier, P., Ottmann, O., Gökbuget, N., Topp, M. S., Fielding, A. K., Rambaldi, A., Ritchie, E. K., Papayannidis, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3531 · Cited by 445
Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 429
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510353 · Cited by 426
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 405
Park, J. H., Geyer, M. B., & Brentjens, R. J. (2016) · Blood · doi:10.1182/blood-2016-02-629063 · Cited by 402
A versatile system for rapid multiplex genome-edited CAR T cell generation
Ren, J., Zhang, X., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.15218 · Cited by 397
Self-citationReynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335
Wang, X., Popplewell, L. L., Wagner, J. R., Naranjo, A., Blanchard, M. S., Mott, M. R., Norris, A. P., Wong, C. W., Urak, R. Z., Chang, W.-C., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686725 · Cited by 322
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Ruella, M., & Maus, M. V. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.003 · Cited by 285
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
(2018) · New England Journal of Medicine · doi:10.1056/nejmc1808251 · Cited by 277
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Qin, H., Ramakrishna, S., Nguyen, S., Fountaine, T. J., Ponduri, A., Stetler-Stevenson, M., Yuan, C. M., Haso, W., Shern, J. F., Shah, N. N., et al. (2018) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2018.10.006 · Cited by 273
Schneider, D., Xiong, Y., Wu, D., Nӧlle, V., Schmitz, S., Haso, W., Kaiser, A., Dropulic, B., & Orentas, R. J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0246-1 · Cited by 262
Fischer, J., Paret, C., El Malki, K., Alt, F., Wingerter, A., Neu, M. A., Kron, B., Russo, A., Lehmann, N., Roth, L., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000169 · Cited by 245
Pan, J., Yang, J. F., Deng, B. P., Zhao, X. J., Zhang, X., Lin, Y. H., Wu, Y. N., Deng, Z. L., Zhang, Y. L., Liu, S. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.145 · Cited by 235
Self-citationFully human CD19-specific chimeric antigen receptors for T-cell therapy
Sommermeyer, D., Hill, T., Shamah, S. M., Salter, A. I., Chen, Y., Mohler, K. M., & Riddell, S. R. (2017) · Leukemia · doi:10.1038/leu.2017.57 · Cited by 220
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
Mirzaei, H. R., Rodriguez, A., Shepphird, J., Brown, C. E., & Badie, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01850 · Cited by 217
Yoon, D., Osborn, M., Tolar, J., & Kim, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020340 · Cited by 215
Singh, H., Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3843 · Cited by 199
CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
Clark, E. A., & Giltiay, N. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02235 · Cited by 197
The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion
Stamenkovic, I., & Seed, B. (1990) · Nature · doi:10.1038/345074a0 · Cited by 186
Inhibitory receptors as targets for cancer immunotherapy
Turnis, M. E., Andrews, L. P., & Vignali, D. A. A. (2015) · European Journal of Immunology · doi:10.1002/eji.201344413 · Cited by 175
Cao, J., Wang, G., Cheng, H., Wei, C., Qi, K., Sang, W., Zhenyu, L., Shi, M., Li, H., Qiao, J., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25108 · Cited by 173
Singh, H., Figliola, M. J., Dawson, M. J., Olivares, S., Zhang, L., Yang, G., Maiti, S., Manuri, P., Senyukov, V., Jena, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064138 · Cited by 170
Allogeneic CAR-T Cells: More than Ease of Access?
Graham, C., Jozwik, A., Pepper, A., & Benjamin, R. (2018) · Cells · doi:10.3390/cells7100155 · Cited by 170
Inhibitory Receptors on Lymphocytes: Insights from Infections
Odorizzi, P. M., & Wherry, E. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100038 · Cited by 167
Assi, R., Kantarjian, H., Short, N. J., Daver, N., Takahashi, K., Garcia-Manero, G., DiNardo, C., Burger, J., Cortes, J., Jain, N., et al. (2017) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2017.08.101 · Cited by 163
Otero, D. C., Anzelon-Mills, A. N., & Rickert, R. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.73 · Cited by 160
Molecular basis of human CD22 function and therapeutic targeting
Ereño-Orbea, J., Sicard, T., Cui, H., Mazhab-Jafari, M. T., Benlekbir, S., Guarné, A., Rubinstein, J. L., & Julien, J.-P. (2017) · Nature Communications · doi:10.1038/s41467-017-00836-6 · Cited by 159
Li, A. M., Hucks, G., DiNofia, A. M., Seif, A. E., Teachey, D. T., Baniewicz, D., Callahan, C. A., Fasano, C., McBride, B., Gonzalez, V. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112572 · Cited by 156
Blaeschke, F., Stenger, D., Kaeuferle, T., Willier, S., Lotfi, R., Kaiser, A. D., Assenmacher, M., Döring, M., Feucht, J., & Feuchtinger, T. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2155-7 · Cited by 155
cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.
Wilson, G. L., Fox, C. H., Fauci, A. S., & Kehrl, J. H. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.1.137 · Cited by 150
The Physiologic Role of CD19 Cytoplasmic Tyrosines
Wang, Y., Brooks, S. R., Li, X., Anzelon-Mills, A. N., Rickert, R. C., & Carter, R. H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00426-0 · Cited by 144
Smith, F. O., Rauch, C., Williams, D. E., March, C., Arthur, D., Hilden, J. M., Lampkin, B., Buckley, J. D., Buckley, C., Woods, W. G., et al. (1996) · Blood · doi:10.1182/blood.v87.3.1123.bloodjournal8731123 · Cited by 129
Zhāng, T., Cao, L., Xie, J., Shi, N., Zhang, Z., Luo, Z., Yue, D., Zhang, Z., Wang, L., Han, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5582 · Cited by 121
Inoue, D., Bradley, R. K., & Abdel-Wahab, O. I. (2016) · Genes & Development · doi:10.1101/gad.278424.116 · Cited by 113
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
Qin, H., Dong, Z., Wang, X., Cheng, W. A., Wen, F., Xue, W., Sun, H., Walter, M., Wei, G., Smith, D. L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw9414 · Cited by 107
Kebriaei, P., Huls, H. M., Jena, B., Munsell, M. F., Jackson, R. N., Lee, D. A., Hackett, P. B., Rondón, G., Shpall, E. J., Champlin, R. E., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.167 · Cited by 103
Chen, Y., Cheng, Y., Suo, P., Yan, C., Wang, Y., Chen, Y., Han, W., Xu, L., Zhang, X., Liu, K., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14923 · Cited by 103
Self-citationMaude, S. L., Hucks, G., Seif, A. E., Talekar, M. K., Teachey, D. T., Baniewicz, D., Callahan, C. A., Gonzalez, V. E., Nazimuddin, F., Gupta, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.103 · Cited by 102
Stein, A. S., Palmer, J. M., Tsai, N., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.067 · Cited by 101
Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
Nicolosi, P. A., Dallatomasina, A., & Perris, R. (2015) · Theranostics · doi:10.7150/thno.10824 · Cited by 85
Schuster, S. J., Svoboda, J., Nasta, S. D., Porter, D., Chong, E. A., Landsburg, D. J., Mato, A. R., Lacey, S. F., Melenhorst, J. J., Chew, A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.183.183 · Cited by 79
Jabbour, E. J., Short, N. J., Jorgensen, J. L., Yilmaz, M. E., Ravandi, F., Wang, S. A., Thomas, D. A., Khoury, J. D., Champlin, R. E., Khouri, I. F., et al. (2016) · Cancer · doi:10.1002/cncr.30264 · Cited by 78
Li, S., Zhang, J., Wang, M., Fu, G., Li, Y., Li, P., Xiong, Z., Qin, D., Zhang, R., Tian, X., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15195 · Cited by 75
Self-citationHeterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia
Himeles, J. R., Naqvi, A. S., Luo, M., Wertheim, G. B. W., Paessler, M. E., Thomas‐Tikhonenko, A., Rheingold, S. R., & Pillai, V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25235 · Cited by 74
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells
Lee, C. V., Hymowitz, S. G., Wallweber, H. J. A., et al. (2006) · Blood · doi:10.1182/blood-2006-03-011031 · Cited by 67
T-Cell Immunotherapy: Looking Forward
Corrigan‐Curay, J., Kiem, H., Baltimore, D., O’Reilly, M., Brentjens, R. J., Cooper, L. J. N., Forman, S. J., Gottschalk, S. M., Greenberg, P. D., Junghans, R. P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.148 · Cited by 65
Gardner, R. A., Annesley, C., Finney, O. C., et al. (2018) · Blood · doi:10.1182/blood-2018-99-113126 · Cited by 65
Guha, P., Cunetta, M., Somasundar, P. S., Espat, N. J., Junghans, R. P., & Katz, S. C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5hi0716-322rr · Cited by 52
Cancer treatment: The killer within
Ledford, H. K. (2014) · Nature · doi:10.1038/508024a · Cited by 51
Park, J. H., Rivière, I., Wang, X., et al. (2015) · Blood · doi:10.1182/blood.v126.23.682.682 · Cited by 48
Amrolia, P. J., Wynn, R., Hough, R. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118616 · Cited by 34
Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line
Cohen, A., Petsche, D., Grunberger, T., & Freedman, M. H. (1992) · Leukemia Research · doi:10.1016/0145-2126(92)90153-x · Cited by 33
Lucero, O. M., Parker, K. N., Funk, T., Dunlap, J. B., Press, R. D., Gardner, R., & Chang, B. H. (2019) · British Journal of Haematology · doi:10.1111/bjh.15812 · Cited by 33
Yang, J., Li, J., Zhang, X., Fanyong, L. V., Guo, X., Wang, Q., Wang, L., Chen, D., Zhou, X., Ren, J.-H., et al. (2018) · Blood · doi:10.1182/blood-2018-99-114415 · Cited by 26
Self-citationMyeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
Perna, F., & Sadelain, M. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.15 · Cited by 24
Shalabi, H., Delbrook, C., Stetler‐Stevenson, M., Yuan, C. M., Steinberg, S. M., Yates, B., Fry, T. J., Lee, D. W., & Shah, N. N. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.018 · Cited by 24
Hasan, A. N., & Selvakumar, A. (2015) · Advancements in Genetic Engineering · doi:10.4172/2169-0111.1000130 · Cited by 22
Huang, L., Wang, N., Li, C., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.846.846 · Cited by 20
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2017) · Scientific Reports · doi:10.1038/srep40272 · Cited by 5
Cited by
Caimi, P. F., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hamadani, M., Hess, B., Kahl, B. S., Radford, J., Solh, M., Stathis, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00139-x · Cited by 441
Self-citationSiegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 282
CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
Clark, E. A., & Giltiay, N. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02235 · Cited by 197
HLA-independent T cell receptors for targeting tumors with low antigen density
Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01621-1 · Cited by 190
Ma, J., Sarén, T., Jin, C., Kim, H. S., Contreras Pineda, P. D., de Bernard, M., Amini, R.-M., Rondahl, V., Enblad, G., Yu, D., et al. (2025) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-025-04112-1 · Cited by 1
Metadata
- Authors
- Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., & Li, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-11-12
- Volume
- 10
- Pages
- 2664-2664
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2988100850
- Cited by
- 347
- References
- 98
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.